http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Baxter to Present at Goldman Sachs 45th Annual Global Healthcare Conference
-
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
-
Baxter to Present at Jefferies 2024 Global Healthcare Conference
-
Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive
-
Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida
-
Baxter (BAX) Wins FDA Approval of Clinolipid Neonatal and Pediatric Indication
-
Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
-
Baxter to Present at Bank of America 2024 Health Care Conference
-
Baxter Declares Quarterly Dividend
-
Nuwellis (NUWE) Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
-
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
-
Baxter Reports First-Quarter 2024 Results
-
Baxter (BAX) Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
-
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
-
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
-
Baxter (BAX) Announces FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software
-
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
-
Baxter to Host Annual Meeting of Stockholders in Virtual Format
-
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
-
Baxter Declares Quarterly Dividend
-
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
-
Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
-
Nuwellis (NUWE) Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
-
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
-
Baxter Advances First Intravenous (IV) Bag Recycling Pilot for U.S. Hospitals
-
Baxter to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Baxter Publishes Task Force on Climate-Related Financial Disclosures (TCFD) Report and Is Named to Dow Jones Sustainability Index North America
-
Nuwellis (NUWE) Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
-
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
-
Baxter Declares Quarterly Dividend
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Baxter Highlights New Data at Kidney Week Indicating Sharesource Is Associated With a 77% Lower Risk of Home Dialysis Technique Failure
-
Baxter Reports Third-Quarter 2023 Results
-
Nuwellis Announces Board of Directors Transition
-
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
-
Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope
-
Baxter (BAX) Appoints Joel Grade Chief Financial Officer
-
Baxter Appoints Joel Grade Chief Financial Officer
-
Baxter to Host Third-Quarter 2023 Financial Results Conference Call for Investors
-
ROSEN, A LEADING LAW FIRM, Encourages Baxter International Inc. Investors With Losses to Secure Counsel Before Important September 11 Deadline in Securities Class Action – BAX
-
Baxter to Present at Morgan Stanley 21st Annual Global Healthcare Conference
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Baxter International Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BAX
-
Advent International and Warburg Pincus Name Franco Negron CEO of BioPharma Solutions Following its Proposed Divestiture from Baxter
-
Baxter to Present at 2023 Wells Fargo Healthcare Conference
-
Baxter (BAX) Announces Board Changes
-
Baxter Announces Updates to Its Board of Directors
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BAX
-
Baxter Reports Second-Quarter 2023 Results
-
Baxter (BAX) Picks Vantive as the Name of Proposed Kidney Care Spinoff
-
Baxter Announces Vantive as the Name of Proposed Kidney Care Spinoff

